Last reviewed · How we verify
AZD0901
AZD0901 is a selective activator of the soluble guanylate cyclase (sGC) enzyme that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.
AZD0901 is a selective activator of the soluble guanylate cyclase (sGC) enzyme that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis. Used for Pulmonary hypertension, Heart failure with preserved ejection fraction (HFpEF).
At a glance
| Generic name | AZD0901 |
|---|---|
| Also known as | Sonesitatug Vedotin, CMG901 |
| Sponsor | AstraZeneca |
| Drug class | Soluble guanylate cyclase (sGC) activator |
| Target | Soluble guanylate cyclase (sGC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Pulmonary |
| Phase | Phase 3 |
Mechanism of action
The drug directly activates soluble guanylate cyclase, a key enzyme in the nitric oxide-cGMP signaling pathway. By increasing cGMP production, AZD0901 promotes smooth muscle relaxation, vasodilation, and anti-fibrotic effects. This mechanism is being explored for cardiovascular and pulmonary conditions where impaired NO-sGC-cGMP signaling contributes to pathology.
Approved indications
- Pulmonary hypertension
- Heart failure with preserved ejection fraction (HFpEF)
Common side effects
- Headache
- Dizziness
- Hypotension
Key clinical trials
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 (PHASE2)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0901 CI brief — competitive landscape report
- AZD0901 updates RSS · CI watch RSS
- AstraZeneca portfolio CI